The first LAG-3 inhibitor combination won the FDA approval for patients with unresectable or metastatic melanoma!
The first LAG-3 inhibitor combination was just approved last week! The FDA approved BMS’ Opdualag, a LAG-3-blocking antibody for patients with unresectable or metastatic melanoma on Friday, March 19th. Opdualag couples relatlimab and PD-1 inhibitor nivolumab: making it the first LAG-3 blocking antibody combination to receive FDA approval. The nod of approval comes from the results of the phase 2/3 RELATIVITY-047 trial after it met its primary endpoint of progression free survival. BMS is quite ahead of its competition that includes 20 other LAG-3 targeting drugs in the pipeline, below is the LAG-3 pipeline in clinical development.?
LAG-3 Targeting Drugs in Clinical Development